Dale Conaway
Direttore/Membro del Consiglio presso BIOXYTRAN, INC.
Patrimonio netto: 126 376 $ in data 30/04/2024
Posizioni attive di Dale Conaway
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOXYTRAN, INC. | Direttore/Membro del Consiglio | 02/11/2018 | - |
Independent Dir/Board Member | 02/11/2018 | - | |
Office of Research Oversight | Direttore Tecnico/Scientifico/R&S | - | - |
Storia della carriera di Dale Conaway
Precedenti posizioni note di Dale Conaway
Società | Posizione | Inizio | Fine |
---|---|---|---|
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Direttore/Membro del Consiglio | - | 03/08/2018 |
Independent Dir/Board Member | - | 03/08/2018 | |
NANOMIX CORPORATION | Direttore/Membro del Consiglio | 01/09/2009 | 15/09/2016 |
Independent Dir/Board Member | 26/03/2012 | 15/09/2016 | |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Direttore/Membro del Consiglio | 10/02/2010 | 30/11/2010 |
GALECTIN THERAPEUTICS INC. | Direttore/Membro del Consiglio | 01/05/2001 | 12/02/2009 |
Federal Research, Inc. | Corporate Officer/Principal | 01/01/2001 | 02/01/2006 |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Direttore/Membro del Consiglio | 01/01/1998 | 01/02/2001 |
Michigan Department of Agriculture | Corporate Officer/Principal | 01/01/1998 | 01/01/2001 |
Formazione di Dale Conaway
Tuskegee University | Doctorate Degree |
Michigan State University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 12 |
Posizioni
Director/Board Member | 6 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Government | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
GALECTIN THERAPEUTICS INC. | Health Technology |
BIOXYTRAN, INC. | Health Technology |
Aziende private | 7 |
---|---|
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Health Technology |
Michigan Department of Agriculture | Government |
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
Office of Research Oversight | |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
Federal Research, Inc. |
- Borsa valori
- Insiders
- Dale Conaway
- Esperienza